In this combined study, including three clinical trials LOXO-TRK-14001 (ClinicalTrials.gov identifier: NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431), a total of 55 patients (age from 4 months to 76 years) with 17 unique TRK fusion-positive tumor types, were enrolled and treated. Here, TPM3 is linked to neoplasm.